Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139


TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.

Bartlett JM, Nielsen TO, Gao D, Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Chen BE, Shepherd LE, Chapman JW.

Br J Cancer. 2015 Aug 18. doi: 10.1038/bjc.2015.271. [Epub ahead of print]


Adverse local tissue reactions in metal-on-polyethylene total hip arthroplasty due to trunnion corrosion: the risk of misdiagnosis.

Whitehouse MR, Endo M, Zachara S, Nielsen TO, Greidanus NV, Masri BA, Garbuz DS, Duncan CP.

Bone Joint J. 2015 Aug;97-B(8):1024-30. doi: 10.1302/0301-620X.97B8.34682.


Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.

Liu FF, Shi W, Done SJ, Miller N, Pintilie M, Voduc D, Nielsen TO, Nofech-Mozes S, Chang MC, Whelan TJ, Weir LM, Olivotto IA, McCready DR, Fyles AW.

J Clin Oncol. 2015 Jun 20;33(18):2035-40. doi: 10.1200/JCO.2014.57.7999. Epub 2015 May 11.


Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA.

Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372. Epub 2015 Apr 23.


CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping.

Nielsen TO, Perou CM.

Clin Cancer Res. 2015 Apr 15;21(8):1779-81. doi: 10.1158/1078-0432.CCR-14-2552.


An international study to increase concordance in Ki67 scoring.

Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Lænkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO.

Mod Pathol. 2015 Jun;28(6):778-86. doi: 10.1038/modpathol.2015.38. Epub 2015 Feb 20.


Cancer genomics: why rare is valuable.

Jamshidi F, Nielsen TO, Huntsman DG.

J Mol Med (Berl). 2015 Apr;93(4):369-81. doi: 10.1007/s00109-015-1260-8. Epub 2015 Feb 14.


A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.

Chu QS, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowling M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA.

Ann Oncol. 2015 May;26(5):973-81. doi: 10.1093/annonc/mdv033. Epub 2015 Jan 28.


Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.

Nielsen TO, Poulin NM, Ladanyi M.

Cancer Discov. 2015 Feb;5(2):124-34. doi: 10.1158/2159-8290.CD-14-1246. Epub 2015 Jan 22. Review.


Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.

Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA.

Breast Cancer Res Treat. 2015 Jan;149(2):439-48. doi: 10.1007/s10549-014-3259-1. Epub 2015 Jan 1.


NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.

Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ, Nielsen TO.

Mod Pathol. 2015 Apr;28(4):587-95. doi: 10.1038/modpathol.2014.155. Epub 2014 Nov 21.


Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C.

Ann Oncol. 2014 Aug;25(8):1536-43. doi: 10.1093/annonc/mdu191. Epub 2014 Jun 9.


Diagnostic value of next-generation sequencing in an unusual sphenoid tumor.

Jamshidi F, Pleasance E, Li Y, Shen Y, Kasaian K, Corbett R, Eirew P, Lum A, Pandoh P, Zhao Y, Schein JE, Moore RA, Rassekh R, Huntsman DG, Knowling M, Lim H, Renouf DJ, Jones SJ, Marra MA, Nielsen TO, Laskin J, Yip S.

Oncologist. 2014 Jun;19(6):623-30. doi: 10.1634/theoncologist.2013-0390. Epub 2014 May 7.


Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.

Nielsen TO, Friis-Hansen L, Poulsen SS, Federspiel B, Sorensen BS.

PLoS One. 2014 Apr 11;9(4):e94606. doi: 10.1371/journal.pone.0094606. eCollection 2014.


The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2014 Mar 1;20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11.


Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer.

Nielsen TO, Borre M, Nexo E, Sorensen BS.

BJU Int. 2015 Jan;115(1):163-5. doi: 10.1111/bju.12658.


Developing a new generation of breast cancer clinical gene expression tests.

Kos Z, Nielsen TO.

Breast Cancer Res. 2014 Jul 7;16(4):103. doi: 10.1186/bcr3688.


HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma.

Nielsen TO, Poulsen SS, Journe F, Ghanem G, Sorensen BS.

Melanoma Res. 2014 Feb;24(1):88-91. doi: 10.1097/CMR.0000000000000040.


PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.

Jørgensen CL, Nielsen TO, Bjerre KD, Liu S, Wallden B, Balslev E, Nielsen DL, Ejlertsen B.

Acta Oncol. 2014 Jun;53(6):776-87. doi: 10.3109/0284186X.2013.865076. Epub 2013 Dec 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk